Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1992-12-18
1995-08-22
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
435 693, 4351723, 4242071, 4242081, 4241841, 4241851, 4241861, 4241871, 530350, 530826, 536 231, 536 234, 536 237, 536 2372, A61K 3921, C12N 1548, C12N 1549
Patent
active
054438284
ABSTRACT:
The chimeric proteins, and a protential vaccine and diagnostic reagent comprising gag-env chimeric protein particles are disclosed. The preparation comprises linking gag of HIV-2 to env to form the chimeric gene, inserting the obtained chimeric gene into the DNA of a baculovirus, infecting insect cells or insect host with the resulting recombinant virus, culturing it and purifying the obtained chimeric protein. The gag chimeric protein of HIV according to the present invention retains both antigenic and immunogenic properties.
REFERENCES:
patent: 4925784 (1990-05-01), Crowl et al.
Wagner, R. et al. Abstract from: Int. Conf. AIDS Jun. 20-23, 1990.
Guyader, M. et al. Nature 326: 662-669 (1987).
Norley, S. et al. Immunobiology 184: 193-207 (1992).
Adams, S. et al Abstract from: AIDS: Antiviral therapy/Immunotherapy/Gene therapy/Sep. 1-8, 1991.
Wagner, R et al. Abstract from: Int. Conf. AIDS Jun. 16-21, 1991.
Griffiths, J. et al. Abstract from: Int Conf. AIDS Jun. 16-21, 1991.
W. G. Robey et al., "Prospect for Prevention of Human Immunodeficiency Virus Infection: Purified 120-kDa Envelope Glycoprotein Induces Neutralizing Antibody", Proc. Natl. Acad. Sci. USA, 83:7023-7027, Sep. 1986.
Per A. Broliden et al., "A Monoclonal Antibody to Human Immunodeficiency Virus Type 1 Which Mediates Cellular Cytotoxocity and Neutralization", Journal of Virology, 64:No. 2:936-940, Feb. 1990.
Hidemi Takahashi et al., "An Immunodominant Epitope of the Human Immunodeficiency Virus Envelope Glycoprotein gp160 Recognized by Class I Major Hisitocompatibility Complex Molecule-restricted Murine Cytotoxic T Lymphocytes", Proc. Natl. Acad. Sci. USA, 85:3105-3109, May 1988.
Hidemi Takahashi et al., "Induction of Broadly Cross-Reactive Cytotoxic T Cells Recognizing an HIV-1 Envelope Determinant", Science, 255:333-336, 17 Jan. 1992.
Gregory J. LaRosa et al., "Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant", Science, 249:932-935, 24 Aug. 1990.
Mark L. Huang et al., "Localization of Immunogenic Domains in the Human Immunodeficiency Virus Type 2 Envelope", Journal of Virology, 65:No. 9:5073-5079, Sep. 1991.
Ewa Bjorling et al., "Hyperimmune Antisera Against Synthetic Peptides Representing the Blycoprotein of Human Immunodeficiency Virus Type 2 Can Mediate Neutralization and Antibody-Dependent Cytotoxic Activity", Proc. Natl. Acad. Sci. USA, 88:6082-6086, Jul. 1991.
Lizhong Luo et al., "Expression of gag Precursor Protein and Secretion of Virus-like gag Particles of HIV-2 from Recombinant Baculovirus-Infected Insect Cells", Virology, 179:874-880, 1990.
C. Yong Kang, "Baculovirus Vectors for Expression of Foreign Genes", Advances in Virus Research, 35:177-192, 1988.
U. K. Laemmmli, "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4", Nature, 227:680-685, 15 Aug. 1970.
Kenneth Garson et al., "The N-Terminal env-Derived Amino Acids of v-re1 are Required for Full Transforming Activity", Virology, 177:106-115, 1990.
Wing L. Sung et al., "Synthesis of Mutant Parathyroid Hormone Genes Via Site-Specific Recombination Directed by Crossover Linkers", Gene, 47:261-267, 1986.
Phillip W. Berman et al., "Protection of Chimpanzees from Infection by HIV-1 after Vaccination with Recombinant Glycoprotein gp120 but not gp160", Nature, 345:622-625, 14 Jun. 1990.
Marc Girard et al., "Immunization of Chimpanzees Confers Protection Against Challenge with Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA, 88:542-546, Jan. 1991.
Scott D. Putney et al. "HTLV-III/LAV-Neutralizing Antibodies to an E. coli-Produced Fragment of the Virus Envelope", Science, 234:1392-1395, 12 Dec. 1986.
Kang Chil-Yong
Luo Lizhong
Korea Green Cross Corporation
Nucker Christine M.
Tuscan M.
LandOfFree
Chimeric HIV-2 gag particles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric HIV-2 gag particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric HIV-2 gag particles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2140344